• Citer

INNODIA Master Protocol for the evaluation of investigational medicinal products in children, adolescents and adults with newly diagnosed type 1 diabetes.

par Dunger, David B;Bruggraber, SFA;Mander, AP;Marcovecchio, ML;Tree, T;Chmura, PJ;Knip, M;Schulte, AM;Mathieu, C;Cnop, Miriam ;And other members of, INNODIA consortium
Référence Trials, 23, 1, page (414)
Publication Publié, 2022-05-01

Article révisé par les pairs

• Accès en ligne
• Détails
• Contenu
• Statistiques

Résumé :

The INNODIA consortium has established a pan-European infrastructure using validated centres to prospectively evaluate clinical data from individuals with newly diagnosed type 1 diabetes combined with centralised collection of clinical samples to determine rates of decline in beta-cell function and identify novel biomarkers, which could be used for future stratification of phase 2 clinical trials.